Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
deselsulfavirine
- Development stage
- Unknown
- Lead developer
- Viriom
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
Deselsulfavirine (VM-1500A) is a small molecule non-nucleoside reverse transcriptase inhibitor (NNRTI) and the active metabolite of the prodrug elsulfavirine. Developed by Viriom Inc., it is being evaluated for the treatment and prevention (PrEP) of HIV-1 infection. Deselsulfavirine works by binding to an allosteric site on the HIV-1 reverse transcriptase enzyme, which inhibits the enzyme's activity and prevents the conversion of viral RNA into DNA, thereby blocking viral replication. The drug is specifically being developed as a long-acting injectable formulation to provide a more convenient dosing schedule and improve adherence compared to daily oral regimens.
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on deselsulfavirine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on deselsulfavirine.